(BBWI) Bath & Body Works - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0708301041

Candles, Soaps, Lotion, Perfume, Sanitizer

BBWI EPS (Earnings per Share)

EPS (Earnings per Share) of BBWI over the last years for every Quarter: "2020-10": 1.13, "2021-01": 3.03, "2021-04": 1.25, "2021-07": 1.34, "2021-10": 0.92, "2022-01": 2.3, "2022-04": 0.64, "2022-07": 0.52, "2022-10": 0.4, "2023-01": 1.86, "2023-04": 0.33, "2023-07": 0.4, "2023-10": 0.48, "2024-01": 2.06, "2024-04": 0.38, "2024-07": 0.37, "2024-10": 0.49, "2025-01": 2.09, "2025-04": 0.49, "2025-07": 0.37, "2025-10": 0,

BBWI Revenue

Revenue of BBWI over the last years for every Quarter: 2020-10: 1702, 2021-01: 4818, 2021-04: 1470, 2021-07: 1704, 2021-10: 1681, 2022-01: 3028, 2022-04: 1450, 2022-07: 1618, 2022-10: 1604, 2023-01: 2888, 2023-04: 1396, 2023-07: 1559, 2023-10: 1562, 2024-01: 2912, 2024-04: 1384, 2024-07: 1526, 2024-10: 1610, 2025-01: 2787, 2025-04: 1424, 2025-07: 1549, 2025-10: null,

Description: BBWI Bath & Body Works July 28, 2025

Bath & Body Works Inc. (BBWI) is a leading specialty retailer in the home fragrance, personal care, and body care markets, offering a diverse range of products including candles, diffusers, fragrances, soaps, lotions, and creams under various brand names. The companys product portfolio is sold through a multi-channel approach, including retail stores and e-commerce platforms in the US and Canada, as well as through international partnerships.

To evaluate BBWIs performance, key performance indicators (KPIs) such as sales growth, same-store sales, gross margin, and operating margin are crucial. The companys ability to maintain a strong brand presence and adapt to changing consumer preferences will be essential in driving future growth. Additionally, metrics like inventory turnover, customer acquisition cost, and customer retention rate can provide insights into the companys operational efficiency and customer loyalty.

From a financial perspective, BBWIs market capitalization and price-to-earnings ratio indicate its market valuation. The companys return on equity (ROE) is negative, suggesting that it may be facing challenges in generating profits. However, a deeper analysis of the companys financial statements, including revenue growth, operating cash flow, and debt-to-equity ratio, would be necessary to understand its underlying financial health.

To further assess BBWIs prospects, it is essential to examine industry trends, competitive landscape, and the companys strategic initiatives. The growing demand for home fragrance and personal care products, driven by consumer preferences for wellness and self-care, presents opportunities for BBWI to expand its market share. The companys e-commerce capabilities, brand diversification, and international partnerships are also critical factors in its growth strategy.

BBWI Stock Overview

Market Cap in USD 5,567m
Sub-Industry Other Specialty Retail
IPO / Inception 1985-07-01

BBWI Stock Ratings

Growth Rating -43.2%
Fundamental 62.4%
Dividend Rating 62.2%
Return 12m vs S&P 500 -33.7%
Analyst Rating 3.85 of 5

BBWI Dividends

Dividend Yield 12m 3.27%
Yield on Cost 5y 4.30%
Annual Growth 5y 34.70%
Payout Consistency 83.0%
Payout Ratio 23.3%

BBWI Growth Ratios

Growth Correlation 3m -76.1%
Growth Correlation 12m -67.3%
Growth Correlation 5y -28.2%
CAGR 5y -6.45%
CAGR/Max DD 3y (Calmar Ratio) -0.12
CAGR/Mean DD 3y (Pain Ratio) -0.25
Sharpe Ratio 12m -0.57
Alpha -38.63
Beta 1.489
Volatility 45.81%
Current Volume 5926.6k
Average Volume 20d 5926.1k
Stop Loss 23.2 (-5.2%)
Signal 0.08

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (728.0m TTM) > 0 and > 6% of Revenue (6% = 442.2m TTM)
FCFTA 0.16 (>2.0%) and ΔFCFTA 2.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 5.47% (prev 2.29%; Δ 3.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.21 (>3.0%) and CFO 1.00b > Net Income 728.0m (YES >=105%, WARN >=100%)
Net Debt (4.63b) to EBITDA (1.56b) ratio: 2.97 <= 3.0 (WARN <= 3.5)
Current Ratio 1.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (211.6m) change vs 12m ago -5.11% (target <= -2.0% for YES)
Gross Margin 44.60% (prev 44.01%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 151.0% (prev 149.2%; Δ 1.76pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 4.42 (EBITDA TTM 1.56b / Interest Expense TTM 292.0m) >= 6 (WARN >= 3)

Altman Z'' 0.91

(A) 0.08 = (Total Current Assets 1.71b - Total Current Liabilities 1.30b) / Total Assets 4.81b
(B) -0.36 = Retained Earnings (Balance) -1.72b / Total Assets 4.81b
(C) 0.26 = EBIT TTM 1.29b / Avg Total Assets 4.88b
(D) -0.24 = Book Value of Equity -1.53b / Total Liabilities 6.36b
Total Rating: 0.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 62.43

1. Piotroski 7.50pt = 2.50
2. FCF Yield 7.68% = 3.84
3. FCF Margin 10.62% = 2.66
4. Debt/Equity -3.23 = -2.50
5. Debt/Ebitda 2.97 = -1.73
6. ROIC - WACC (= 29.26)% = 12.50
7. RoE -47.48% = -2.50
8. Rev. Trend -11.00% = -0.82
9. EPS Trend -30.22% = -1.51

What is the price of BBWI shares?

As of November 03, 2025, the stock is trading at USD 24.48 with a total of 5,926,600 shares traded.
Over the past week, the price has changed by -5.99%, over one month by -4.60%, over three months by -14.42% and over the past year by -19.69%.

Is Bath & Body Works a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Bath & Body Works is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 62.43 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BBWI is around 22.42 USD . This means that BBWI is currently overvalued and has a potential downside of -8.42%.

Is BBWI a buy, sell or hold?

Bath & Body Works has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy BBWI.
  • Strong Buy: 7
  • Buy: 4
  • Hold: 8
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the BBWI price?

Issuer Target Up/Down from current
Wallstreet Target Price 38.8 58.6%
Analysts Target Price 38.8 58.6%
ValueRay Target Price 24.6 0.3%

BBWI Fundamental Data Overview October 27, 2025

Market Cap USD = 5.57b (5.57b USD * 1.0 USD.USD)
P/E Trailing = 8.0838
P/E Forward = 6.7522
P/S = 0.7553
P/EG = 0.7168
Beta = 1.489
Revenue TTM = 7.37b USD
EBIT TTM = 1.29b USD
EBITDA TTM = 1.56b USD
Long Term Debt = 3.89b USD (from longTermDebt, last quarter)
Short Term Debt = 194.0m USD (from shortTermDebt, last quarter)
Debt = 4.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.63b USD (from netDebt column, last quarter)
Enterprise Value = 10.20b USD (5.57b + Debt 4.99b - CCE 364.0m)
Interest Coverage Ratio = 4.42 (Ebit TTM 1.29b / Interest Expense TTM 292.0m)
FCF Yield = 7.68% (FCF TTM 783.0m / Enterprise Value 10.20b)
FCF Margin = 10.62% (FCF TTM 783.0m / Revenue TTM 7.37b)
Net Margin = 9.88% (Net Income TTM 728.0m / Revenue TTM 7.37b)
Gross Margin = 44.60% ((Revenue TTM 7.37b - Cost of Revenue TTM 4.08b) / Revenue TTM)
Gross Margin QoQ = 41.32% (prev 45.37%)
Tobins Q-Ratio = 2.12 (Enterprise Value 10.20b / Total Assets 4.81b)
Interest Expense / Debt = 1.36% (Interest Expense 68.0m / Debt 4.99b)
Taxrate = 32.63% (31.0m / 95.0m)
NOPAT = 869.1m (EBIT 1.29b * (1 - 32.63%))
Current Ratio = 1.31 (Total Current Assets 1.71b / Total Current Liabilities 1.30b)
Debt / Equity = -3.23 (negative equity) (Debt 4.99b / totalStockholderEquity, last quarter -1.55b)
Debt / EBITDA = 2.97 (Net Debt 4.63b / EBITDA 1.56b)
Debt / FCF = 5.91 (Net Debt 4.63b / FCF TTM 783.0m)
Total Stockholder Equity = -1.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.12% (Net Income 728.0m / Total Assets 4.81b)
RoE = -47.48% (negative equity) (Net Income TTM 728.0m / Total Stockholder Equity -1.53b)
RoCE = 54.78% (EBIT 1.29b / Capital Employed (Equity -1.53b + L.T.Debt 3.89b))
RoIC = 35.76% (NOPAT 869.1m / Invested Capital 2.43b)
WACC = 6.50% (E(5.57b)/V(10.56b) * Re(11.50%) + D(4.99b)/V(10.56b) * Rd(1.36%) * (1-Tc(0.33)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.66%
[DCF Debug] Terminal Value 64.92% ; FCFE base≈744.2m ; Y1≈683.3m ; Y5≈611.0m
Fair Price DCF = 32.10 (DCF Value 6.62b / Shares Outstanding 206.2m; 5y FCF grow -10.28% → 3.0% )
EPS Correlation: -30.22 | EPS CAGR: -74.59% | SUE: -4.0 | # QB: 0
Revenue Correlation: -11.00 | Revenue CAGR: -1.26% | SUE: -0.19 | # QB: 0

Additional Sources for BBWI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle